TYRA-430
- Generic Name
- TYRA-430
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Phase 1
Recruiting
- Conditions
- Metastatic Hepatocellular CarcinomaSolid Tumor, AdultFGFR4 Gene MutationFGFR3 Gene FusionsSolid TumorsFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationAdvanced Solid TumorsFGFR Gene Amplification
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Tyra Biosciences, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT06915753
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath